Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222117 · ClinicalTrials.gov registry record · Phase 2
A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
A Phase 2 study, sponsored by Grifols Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT01222117 is a Phase 2 study that has completed, run by Grifols Therapeutics. The registered enrollment target is 174 participants.
The verdict
NCT01222117, a Phase 2 study, has completed, sponsored by Grifols Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
The primary purpose of this Phase 2 study is to optimize Plasmin delivery by comparing different delivery regimens in patients with peripheral arterial occlusion. The study includes a blinded plasminogen activator treatment group and a blinded plasminogen activator placebo group. The study will also assess safety and tolerability of Plasmin at 150 and 250 mg doses.
Interventions
- OTHER Placebo
- BIOLOGICAL Plasmin
- BIOLOGICAL Plasminogen Activator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2010-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01222117
The ClinicalTrials.gov registry entry for NCT01222117 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grifols Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01222117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01222117 about?
NCT01222117 is a clinical study titled "A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion". The primary purpose of this Phase 2 study is to optimize Plasmin delivery by comparing different delivery regimens in patients with peripheral arterial occlusion. The study includes a blinded plasminogen activator treatment group and a blinded plasminogen activator placebo group. The study will also...
What is the current status of trial NCT01222117?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2010-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01222117?
The interventions under investigation include: Placebo (OTHER), Plasmin (BIOLOGICAL), Plasminogen Activator (BIOLOGICAL).
Who is sponsoring clinical trial NCT01222117?
This trial is sponsored by Grifols Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.